BIOSIGHT
BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.
BIOSIGHT
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2000-01-01
Address:
Carmiel, HaZafon, Israel
Country:
Israel
Website Url:
http://www.biosight-pharma.com
Total Employee:
1+
Status:
Active
Contact:
972 4 958 1519
Email Addresses:
[email protected]
Total Funding:
59 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
Alphamab Oncology
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Innovative Cellular Therapeutics
Innovative Cellular Therapeutics is a Shanghai-based biotechnology company engaged in research and development of cell therapy.
KBP Biosciences
A multinational clinical stage biotechnology company.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Current Employees Featured
Founder
Investors List
Migdal Insurance and Financial Holdings
Migdal Insurance and Financial Holdings investment in Series C - BioSight
Israel Biotech Fund
Israel Biotech Fund investment in Series C - BioSight
Arkin Bio Ventures
Arkin Bio Ventures investment in Series C - BioSight
Primera Capital
Primera Capital investment in Series C - BioSight
Phoenix Insurance Company
Phoenix Insurance Company investment in Series C - BioSight
Biotel
Biotel investment in Series C - BioSight
Arkin Bio Ventures
Arkin Bio Ventures investment in Series C - BioSight
Israel Biotech Fund
Israel Biotech Fund investment in Series C - BioSight
SBI Japan-Israel Innovation Fund
SBI Japan-Israel Innovation Fund investment in Series C - BioSight
Arkin Holdings
Arkin Holdings investment in Venture Round - BioSight
Official Site Inspections
http://www.biosight-pharma.com Semrush global rank: 4.05 M Semrush visits lastest month: 3.02 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "BioSight"
BioSight - Innovative Cancer Therapeutics
BioSight is a pharmaceutical development company, developing novel cancer-targeted drugs. BioSight's BST-236 is developed for acute myeloid leukemia treatment.See details»
BioSight - Crunchbase Company Profile & Funding
Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological.See details»
Biosight Ltd. - LinkedIn
Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders. Biosight’s lead product, BST-236 (aspacytarabine ...See details»
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger …
Jul 27, 2023 Pini Orbach, PhD, Chairman of Biosight, commented, “The Ayala team shares our commitment to bringing innovative treatments to cancer patients in need and we are excited to …See details»
BioSight 2025 Company Profile: Valuation, Investors, Acquisition ...
Information on acquisition, funding, investors, and executives for BioSight. Use the PitchBook Platform to explore the full profile.See details»
BioSight - LinkedIn
BioSight is Biopharmaceutical Company focused on the development of peptide-based targeted drugs, for unmet clinical needs, in specifically cancer targeted chemotherapy. BioSight also provide ...See details»
Biosight (Israel) Funding: $59M - Medical Startups
4 days ago BioSight is a biopharmaceutical company revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that …See details»
Biosight Company Profile - Office Locations, Competitors ... - Craft
Biosight has 5 employees at their 1 location and $32 m in total funding,. See insights on Biosight including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Biosight - Overview, News & Similar companies | ZoomInfo.com
Aug 1, 2022 View Biosight (www.biosight-pharma.com) location in Northern District, Israel , revenue, industry and description. Find related and similar companies as well as employees …See details»
BioSight - VentureRadar
BioSight is a private pharmaceutical development company founded in 2000. We focus on development of novel anti-cancer drugs and novel chemotherapy pro-drugs, addressing unmet …See details»
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
The combined company will operate under the name Ayala Pharmaceuticals, Inc., and its shares will continue to trade on the OTCQX under Ayala’s current ticker symbol (“ADXS”). “We are …See details»
BioSight - Israeli Startup | Startup Nation Finder
Dec 2, 2020 Biosight is a phase-2 clinical-stage biotechnology company developing therapeutics for Hematological Malignancies and disorders. Biosight's lead product, BST-236 (INN …See details»
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
Oct 19, 2023 REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology …See details»
BioSight Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Explore BioSight Ltd. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 22 news, and 13 literature, Disease Domain:Hemic and Lymphatic ...See details»
BioSight - Products, Competitors, Financials, Employees, …
About BioSight Biosight is a clinical-stage hemato-oncology company. It focuses on the development of therapeutics and treatments for oncological and hematological disorders. The …See details»
BioSight - The Trendlines Group
Trendlines’ shares in BioSight were acquired by Arkin Bio Ventures Ltd. in June 2017. BioSight develops advanced therapeutics to enable safe and effective treatment for life-threatening …See details»
Advaxis and Biosight Announce Entry into Definitive Merger …
Jul 6, 2021 The proposed merger will create a public company that will prioritize the clinical advancement and commercialization of Biosight’s lead product, aspacytarabine (BST-236).See details»
Advaxis and Biosight Announce Entry into Definitive Merger
Jul 6, 2021 Advaxis, Inc. and Biosight Ltd., a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, …See details»
Ayala Pharmaceuticals and Biosight Enter into Merger Agreement
Jul 28, 2023 Ayala Pharmaceuticals and Biosight are merging to harness their assets and expertise in oncology, accelerating the development of promising drugs, including AL102 and …See details»
Biosight Closes $46M Series C Financing to Advance Clinical
Dec 2, 2020 Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs Proceeds support expanded clinical program of BST-236, a proprietary anti-metabolite …See details»